Bevacizumab Improves Pathologic Response and Protects Against Hepatic Injury in Patients Treated With Oxaliplatin-Based Chemotherapy for Colorectal Liver Metastases
BACKGROUND. The current study evaluated the effect of bevacizumab added to fluoropyrimidine-plus-oxaliplatin (5FU/OX) chemotherapy for colorectal liver metastases (CLM) on the pathologic response and nontumorous liver histology. METHODS. A total of 105 consecutive patients treated preoperatively wit...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , , , |
| التنسيق: | article |
| منشور في: |
2007
|
| الوصول للمادة أونلاين: | http://hdl.handle.net/10725/2578 http://dx.doi.org/10.1002/cncr.23099 https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.23099 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|